45 An integrative immune signature of complementary circulating and tumoral biomarkers maximizes the predictive power of adjuvant immunotherapeutic benefits for high-risk melanoma

• Lisa H Butterfield,
• Howard Streicher,
• Patrick Hwu,
• Walter J Storkus,
• Ahmad A Tarhini,
• John M Kirkwood,
• F Stephen Hodi,
• Dung-Tsa Chen,
• Sandra J Lee,
• Issam El Naqa,
• William A LaFramboise,
• Arivarasan D Karunamurthy,
• Timothy I Shaw,
• Alyssa Obermayer

Affiliations

Lisa H Butterfield

7Merck Research Laboratories, South San Francisco, CA, USA

Howard Streicher

5National Cancer Institute, Bethesda, MD, USA

Patrick Hwu

1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Walter J Storkus

6University of Pittsburgh, Pittsburgh, PA, USA

Ahmad A Tarhini

1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

John M Kirkwood

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA

F Stephen Hodi

2Dana-Farber Cancer Institute, Boston, MA, USA

Dung-Tsa Chen

1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Sandra J Lee

2Dana-Farber Cancer Institute, Boston, MA, USA

Issam El Naqa

1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

William A LaFramboise

3Allegheny Health Network, Pittsburgh, PA, USA

Arivarasan D Karunamurthy

4UPMC Hillman Cancer Center, Pittsburgh, PA, USA

Timothy I Shaw

1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Alyssa Obermayer

1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA